Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with non-small cell lung cancer (either adenocarcinoma or squamous cell carcinoma).
- Your cancer is stage IIB (tumor larger than 4 cm), IIIA, or IIIB where the lymph node involvement is limited and can be surgically removed (N2 only, not bulky).
- If you have adenocarcinoma, you must have been tested and do not have an EGFR mutation or ALK rearrangement; if you have squamous cell cancer, you don't need this test unless you know you have one of these mutations.
- You are healthy enough for major lung surgery and your lung function is adequate (FEV1 and MVV at least 50% of predicted).
- You have not had any previous treatment for your lung cancer, including chemotherapy or radiation, and you are not taking long-term steroids or have serious autoimmune diseases or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
Hear when a new Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.